Resistance to tamoxifen therapy in some estrogen receptor positive breast cancers may originate from in utero exposure to endocrine disrupting chemicals, research in animal studies suggests. This study provides a new path forward in human research as about half of the breast cancers treated with this common cancer therapy do not respond well, say researchers.
Link: Tamoxifen resistance linked to high estrogen levels in utero
Source: Gynecology Science Daily